[go: up one dir, main page]

MA53688B1 - Anticorps monoclonaux qui se lient spécifiquement à trbv-9 de l'humain - Google Patents

Anticorps monoclonaux qui se lient spécifiquement à trbv-9 de l'humain

Info

Publication number
MA53688B1
MA53688B1 MA53688A MA53688A MA53688B1 MA 53688 B1 MA53688 B1 MA 53688B1 MA 53688 A MA53688 A MA 53688A MA 53688 A MA53688 A MA 53688A MA 53688 B1 MA53688 B1 MA 53688B1
Authority
MA
Morocco
Prior art keywords
antibody
human
monoclonal antibodies
trbv
specifically bind
Prior art date
Application number
MA53688A
Other languages
English (en)
Other versions
MA53688A1 (fr
Inventor
Timofey Aleksandrovich Nemankin
Roman Alekseevich Ivanov
Pavel Andreevich Iakovlev
Anna Konstantinovna Vladimirova
?Lga Vladimirovna Britanova
Mariia Aleksandrovna Shchemeleva
Alexey Konstantinovich Misorin
Dmitry Borisovich Staroverov
Anna Valentinovna Evstrateva
Arina Vitalevna Anikina
Dmitry Valentinovichvna Morozov
Sergey Anatolievichvna Lukyanov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2018146029A external-priority patent/RU2711871C3/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MA53688A1 publication Critical patent/MA53688A1/fr
Publication of MA53688B1 publication Critical patent/MA53688B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un anticorps monoclonal humanisé ou son fragment de liaison d'antigène qui se lient spécifiquement à la famille trbv-9 des récepteurs cellulaires t de l'humain. L'invention concerne également un acide nucléique codant pour cet anticorps ou un fragment de liaison à un antigène de celui-ci, un vecteur d'expression, un procédé de production d'un anticorps et l'utilisation d'un anticorps pour traiter des maladies ou des troubles associés à la famille des récepteurs des lymphocytes t humains. L'invention vise notamment la création d'anticorps qui peuvent être utilisés pour la thérapie, notamment lors d'une spondylarthrite ankylosante (sa ou maladie de bechterew), de la la maladie cœliaque et des maladies sanguines malignes dont la pathogenèse est liée à l'implication des récepteurs des cellules t trbv9.
MA53688A 2018-12-25 2019-12-24 Anticorps monoclonaux qui se lient spécifiquement à trbv-9 de l'humain MA53688B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2018146029A RU2711871C3 (ru) 2018-12-25 Моноклональные антитела, которые специфически связываются с участком бета цепи семейства TRBV-9 Т-клеточного рецептора человека, и способы их применения
PCT/RU2019/050257 WO2020139171A1 (fr) 2018-12-25 2019-12-24 Anticorps monoclonaux qui se lient spécifiquement à trbv-9 de l'humain

Publications (2)

Publication Number Publication Date
MA53688A1 MA53688A1 (fr) 2022-06-30
MA53688B1 true MA53688B1 (fr) 2023-03-31

Family

ID=69184146

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53688A MA53688B1 (fr) 2018-12-25 2019-12-24 Anticorps monoclonaux qui se lient spécifiquement à trbv-9 de l'humain

Country Status (25)

Country Link
US (1) US12297269B2 (fr)
EP (1) EP3904387A4 (fr)
JP (1) JP7507160B2 (fr)
KR (1) KR20210118843A (fr)
CN (1) CN113692412B (fr)
AR (1) AR117735A1 (fr)
AU (1) AU2019416787A1 (fr)
BR (1) BR112021012550A2 (fr)
CA (1) CA3124800A1 (fr)
CL (1) CL2021001704A1 (fr)
CO (1) CO2021008204A2 (fr)
CR (1) CR20210353A (fr)
EA (1) EA202100199A1 (fr)
EC (1) ECSP21046332A (fr)
IL (1) IL284367A (fr)
JO (1) JOP20210168A1 (fr)
MA (1) MA53688B1 (fr)
MX (1) MX2021007718A (fr)
MY (1) MY206214A (fr)
PE (1) PE20211792A1 (fr)
PH (1) PH12021551535A1 (fr)
SG (1) SG11202106974SA (fr)
TW (1) TW202033557A (fr)
WO (1) WO2020139171A1 (fr)
ZA (1) ZA202104356B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2694412C9 (ru) * 2017-12-25 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Моноклональные антитела и способы их применения
EP3737692A4 (fr) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. Constructions de liaison à la calréticuline et lymphocytes t modifiés pour le traitement de maladies
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020010250A2 (fr) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Molécules d'anticorps anti-tcr et leurs utilisations
CN119661722A (zh) 2019-02-21 2025-03-21 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
WO2021138474A2 (fr) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Molécules d'anticorps anti-tcr et leurs utilisations
WO2025075529A1 (fr) * 2023-10-04 2025-04-10 Joint Stock Company "Biocad" Anticorps monoclonal ou fragment de liaison à l'antigène de celui-ci qui se lie spécifiquement au segment trbv5-1 du domaine variable de chaîne bêta du récepteur de lymphocytes t humains, et son utilisation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
US6881557B2 (en) * 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
EP2446052B1 (fr) 2009-06-25 2018-08-08 Fred Hutchinson Cancer Research Center Procédé de mesure de l'immunité adaptative
TW201208701A (en) 2010-07-12 2012-03-01 Daiichi Sankyo Co Ltd Anti-EPHA2 antibodies and uses thereof
US20130273089A1 (en) * 2011-11-03 2013-10-17 Tolera Therapeutics, Inc. Antibody and methods for selective inhibition of t-cell responses
WO2014177771A1 (fr) 2013-05-02 2014-11-06 Glykos Finland Oy Conjugués d'une glycoprotéine ou d'un glycane avec une charge toxique
EP3202784A1 (fr) 2016-02-08 2017-08-09 Polybiocept AB Séquences de récepteurs de lymphocytes t pour une immunothérapie active
CA3022129A1 (fr) 2016-06-17 2017-12-21 Medigene Immunotherapies Gmbh Recepteurs de lymphocytes t et leurs utilisations
RU2019116312A (ru) 2016-11-14 2020-12-14 Фред Хатчинсон Кэнсер Рисерч Сентер Высокоаффинные tcr, специфичные к t-антигену полиомавируса клеток меркеля, и их применения
US20200040085A1 (en) 2017-02-27 2020-02-06 Chugai Seiyaku Kabushiki Kaisha Anti-hla-dq2.5/8 antibody and its use for the treatment of celiac disease
CN107502671B (zh) * 2017-10-12 2020-05-05 中国医学科学院肿瘤医院 利用trbv家族成员预测曲妥珠单抗新辅助治疗乳腺癌患者疗效试剂盒及其应用
RU2694412C9 (ru) 2017-12-25 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Моноклональные антитела и способы их применения

Also Published As

Publication number Publication date
EP3904387A1 (fr) 2021-11-03
US12297269B2 (en) 2025-05-13
IL284367A (en) 2021-08-31
PH12021551535A1 (en) 2022-02-28
MY206214A (en) 2024-12-04
ECSP21046332A (es) 2021-07-30
JOP20210168A1 (ar) 2023-01-30
JP7507160B2 (ja) 2024-06-27
CA3124800A1 (fr) 2020-07-02
CR20210353A (es) 2021-12-20
EA202100199A1 (ru) 2021-12-02
RU2711871C1 (ru) 2020-01-23
MA53688A1 (fr) 2022-06-30
PE20211792A1 (es) 2021-09-09
EP3904387A4 (fr) 2022-09-07
CN113692412B (zh) 2024-08-16
TW202033557A (zh) 2020-09-16
WO2020139171A1 (fr) 2020-07-02
BR112021012550A2 (pt) 2021-09-14
AR117735A1 (es) 2021-08-25
JP2022515820A (ja) 2022-02-22
CL2021001704A1 (es) 2022-01-28
CO2021008204A2 (es) 2021-08-30
US20220056133A1 (en) 2022-02-24
SG11202106974SA (en) 2021-07-29
AU2019416787A1 (en) 2021-08-12
CN113692412A (zh) 2021-11-23
MX2021007718A (es) 2021-08-05
KR20210118843A (ko) 2021-10-01
ZA202104356B (en) 2022-09-28

Similar Documents

Publication Publication Date Title
MA53688A1 (fr) Anticorps monoclonaux qui se lient spécifiquement à trbv-9 de l'humain
MA53689A1 (fr) Anticorps humanisés contre un fragment bêta d'une chaîne de la famille 9 du récepteur cellulaire trbv-9 de l'humain et méthodes de leur application
MA50128B1 (fr) Anticorps monoclonaux liants le recepteur trbv9 des lymphocytes t et procédés de leur utilisation
AU2016292892B2 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
US10364286B2 (en) Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
TWI678376B (zh) 經改良之Ａβ原纖維結合抗體
MA31246B1 (fr) Anticorps antagoniste d'ox40, et leur utilisation dans le traitement de maladies inflammatoires et auto-immunes
JOP20210265A1 (ar) الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها
JP2023157927A (ja) 多発性骨髄腫におけるｍタンパク質反応の臨床評価
CN111518205B (zh) 人源化抗Aβ单克隆抗体及其应用
JPS6312297A (ja) ヒトインタ−ロイキン−２−リセプタ−を認識するモノクロ−ナル抗体
MA44917B1 (fr) Anticorps ou son fragment de liaison d’antigènes apte a se lier au récepteur d'interleukine-6 de l'humain.
Suzuki et al. Idiotypic and fine specificity analysis of a (4‐hydroxy‐3‐nitrophenyl) acetyl (NP)‐specific suppressor T cell hybridoma at the level of cell surface structures, isolated receptor material and functional suppressor factor
Nishinarita et al. IgA isotype-restricted idiotypes associated with T15 Id+ PC antibodies.
CN112153983B (zh) 抗ngly-1抗体及使用方法
JP7256172B2 (ja) ミニブタ試料において抗薬物抗体を決定するための方法
WO2024012434A1 (fr) Anticorps, fragment de liaison à l'antigène de celui-ci, et leur utilisation pharmaceutique
WO2024012513A1 (fr) Anticorps, fragment de liaison à l'antigène de celui-ci, et utilisation pharmaceutique associée
Poston et al. Specific enzyme treatment is required for individual monoclonal antibodies in immunohistochemistry with formalin fixed sections
Ramberger et al. Synaptic autoimmunity: new insights into LGI1 antibody-mediated neuronal dysfunction
CN119039448A (zh) 特异性结合抗人tim-3抗体的抗独特型抗体及其用途
JP2017019755A (ja) 標識免疫複合体を用いたアレルギー反応迅速識別法およびその誘導試薬キット
WO2019031444A1 (fr) Procédé de mesure du taux d'occupation de substances de liaison spécifiques dans une population cellulaire
JP2009139372A (ja) ラットＩｇＥ測定試薬
OA18779A (en) Antibodies Specific for Hyperphosphorylated Tau and Methods of Use Thereof.